OSE Immunotherapeutics - Timely FR104/VEL-101 update with Phase II plans
OSE Immunotherapeutics (OSE) has shared a positive update on the FIRsT clinical trial assessing FR104/VEL-101 (an anti-CD28 monoclonal antibody) as...
253 Views
OSE Immunotherapeutics - Collaboration bolsters upcoming Tedopi Phase III
OSE Immunotherapeutics (OSE) has announced a collaboration with GenDx for the development and validation of a companion diagnostic screening test...
211 Views
OSE Immunotherapeutics - Anticipation builds with positive OSE-279 data
At the AACR-NCI-EORTC conference in Boston, OSE presented the initial positive data supporting the potential efficacy of its anti-PD1 monoclonal...
211 Views
OSE Immunotherapeutics - Maintaining momentum after an active H123
OSE Immunotherapeutics (OSE) has announced its H123 results, providing an operational and a financial update. Highlights from the period included...
237 Views
OSE Immunotherapeutics - Publication puts Tedopi back in the spotlight
OSE has announced that the results from its Phase III trial (ATALANTE-1) for Tedopi have been published in Annals of Oncology. While the study...
362 Views